Jump to content

U-90042

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Kku (talk | contribs) at 10:25, 14 August 2018 (link Novo Nordisk using Find link). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

U-90042
Identifiers
  • 11-Chloro-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydrodiimidazo[1,2-c:1',5'-a]quinazoline
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H13ClN6O
Molar mass352.78 g/mol g·mol−1
3D model (JSmol)
  • ClC1=CC2=C(C=C1)N3C=NC(C4=NOC(C5CC5)=N4)=C3N6C2=NCC6
  • InChI=1S/C17H13ClN6O/c18-10-3-4-12-11(7-10)15-19-5-6-23(15)17-13(20-8-24(12)17)14-21-16(25-22-14)9-1-2-9/h3-4,7-9H,1-2,5-6H2 ☒N
  • Key:CLPSAAPUJUVQPP-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

U-90042 is a sedative and hypnotic drug used in scientific research. It has similar effects to sedative-hypnotic benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine hypnotic.

U-90042 is a GABAA agonist acting primarily at the α1, α3 and α6 subtypes, with a Ki of 7.8nM at α1, 9.5nM at α3 and 11.0nM at α6. It produces sedation and ataxia and prolongs sleeping time in mice, rats and monkeys, but does not produce amnesia and blocks the amnestic effect of diazepam, reflecting its different subtype affinity compared to benzodiazepine drugs.[1] It was developed by a team at Novo Nordisk in the 1980s.[2]

References

  1. ^ Tang, AH; Smith, MW; Carter, DB; Im, WB; Vonvoigtlander, PF (1995). "U-90042, a sedative/hypnotic compound that interacts differentially with the GABAA receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 275 (2): 761–7. PMID 7473164.
  2. ^ US Patent 5100895 Heterocyclic compounds and their preparation and use